New Settings for Immune Checkpoint Inhibitors in Urothelial Bladder Cancer
With many new indications for immune checkpoint inhibitors in urothelial bladder cancer, as well as a number of important ongoing trials using these agents, timely education on this topic is important.
Category
  • Bladder Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Update: Multiple Myeloma
Clinicians must understand the evolving therapeutic options and guidelines for administration of the available therapies in the context of the patient's therapeutic and disease history to navigate through the complex treatment landscape.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Updates: Uterine Cancers
Uterine sarcomas and carcinosarcomas vary in presentation, but are generally aggressive tumors with a poor prognosis; therefore, accurate diagnosis of these tumor types is critical. Biomarker testing/molecular profiling may be used in combination with histopathological assessment to improve diagnosis, determine prognosis, and optimize treatment selection.
Category
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Treatment of Locally Advanced Colorectal Cancer
Trimodal therapy approaches for localized rectal cancer continue to evolve as new data helps define how to best improve outcomes while reducing adverse effects, with total neoadjuvant therapy (TNT) among the approaches of recent interest.  Additionally, new therapies have substantially expanded the treatment options for mCRC in recent years.
Category
  • Colorectal Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates in the Management of CLL/SLL: Management of Relapsed/Refractory Disease and the Role of Minimal Residual Disease
The therapeutic landscape of chronic lymphocytic leukemia (CLL) has evolved significantly in recent years, and the use of targeted therapy with small molecule inhibitors in the first-line setting will significantly alter the management of relapsed/refractory disease.
Category
  • Chronic Lymphocytic Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options
Novel systemic therapy treatment options for patients with advanced thyroid carcinoma continue to be evaluated, including for anaplastic disease, which is almost uniformly lethal. Because some patients with medullary thyroid carcinoma may have indolent and asymptomatic disease, potentially toxic therapy may not be appropriate.
Category
  • Thyroid Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Use of PARP Inhibitors for Ovarian Cancer
The data on PARP inhibitors for treatment of ovarian, primary peritoneal, or fallopian tube cancers has led to substantial changes in the recommendations for molecular testing, maintenance after first-line therapy, recurrence therapy, and maintenance after recurrence therapy.
Category
  • Ovarian Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
New Systemic Treatment Options for Hepatobiliary Cancers
In recent years, multiple treatment options were added for the first-line treatment of hepatocellular carcinoma as well as for first- and subsequent-line treatment of biliary tract cancers. As molecular profiling can help identify eligibility for more targeted clinical trials or therapies, physicians should consider gene testing. Knowledge of the new therapies will help better inform clinical decision-making.
Category
  • Hepatocellular Carcinoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Updates on CAR T-cell Therapy for Relapsed/Refractory B-Cell Lymphomas
There is a clear need to educate clinicians regarding the special considerations for the administration of CAR T-cell therapy in appropriately selected patients, the unique spectrum of adverse events and effective management strategies.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Evolving Treatment Options for Salivary Gland Tumors
NCCN Guidelines recommendations regarding treatment of salivary gland tumors have recently been considerably revised, notably systemic therapy recommendations.
Category
  • Head and Neck Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages